Backed by extensive experience in the biotechnology and life sciences sectors, the fund manager has executed over 30 deals across North America and Europe. Their strategic style emphasizes a data-driven approach, focusing on early to growth-stage investments that drive innovation. Notable exits include several high-profile acquisitions, demonstrating a strong track record of value creation. With a commitment to thematic investing, they actively seek opportunities that address critical healthcare challenges.